Excedrin Tablet, Film Coated
NDC Package 0067-2000-33
Package Information
Excedrin (acetaminophen, aspirin (nsaid), and caffeine) tablets is •do not use more than directed•adults and children 12 years and over: take 2 caplets every 6 hours; not more than 6 caplets in 24 hours•children under 12 years: ask a doctor •do not use more than directed•drink a full glass of water with each dose•adults and children 12 years and over: take 2 caplets every 6 hours; not more than 8 caplets in 24 hours•children under 12 years: ask a doctor. This formulation utilizes a tablet, film coated delivery system. Marketed by Haleon Us Holdings Llc, this product is identified by NDC 0067-2000 and is authorized under FDA application M013.
Identification & Billing
- RxCUI: 209468 - EXCEDRIN 250 MG / 250 MG / 65 MG Oral Tablet
- RxCUI: 209468 - acetaminophen 250 MG / aspirin 250 MG / caffeine 65 MG Oral Tablet [Excedrin]
- RxCUI: 209468 - APAP 250 MG / ASA 250 MG / Caffeine 65 MG Oral Tablet [Excedrin]
- RxCUI: 209468 - Excedrin Extra Strength (APAP 250 MG / ASA 250 MG / caffeine 65 MG) Oral Tablet
- RxCUI: 209468 - Excedrin Menstrual Complete (APAP 250 MG / ASA 250 MG / caffeine 65 MG) Oral Tablet
Clinical Specifications
- Anti-Inflammatory Agents, Non-Steroidal - [CS]
- Central Nervous System Stimulant - [EPC] (Established Pharmacologic Class)
- Central Nervous System Stimulation - [PE] (Physiologic Effect)
- Cyclooxygenase Inhibitors - [MoA] (Mechanism of Action)
- Decreased Platelet Aggregation - [PE] (Physiologic Effect)
- Decreased Prostaglandin Production - [PE] (Physiologic Effect)
- Methylxanthine - [EPC] (Established Pharmacologic Class)
- Nonsteroidal Anti-inflammatory Drug - [EPC] (Established Pharmacologic Class)
- Platelet Aggregation Inhibitor - [EPC] (Established Pharmacologic Class)
- Xanthines - [CS]
Regulatory & Marketing
Hierarchy Structure
- 0067 - Haleon Us Holdings Llc
- 0067-2000 - Excedrin
- 0067-2000-33 - 1 BOTTLE in 1 CARTON / 300 TABLET, FILM COATED in 1 BOTTLE
- 0067-2000 - Excedrin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0067-2000). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0067-2000-33 identifies a specific commercial package of 1 bottle in 1 carton / 300 tablet, film coated in 1 bottle of Excedrin Extra Strength Pain Reliever, a human over the counter drug labeled by Haleon Us Holdings Llc. This tablet, film coated is formulated for oral use and contains acetaminophen; aspirin; caffeine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Haleon Us Holdings Llc on September 27, 2006. The current certification is valid through December 31, 2026.
How is this Haleon Us Holdings Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00067200033. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.